Ben D. Singer


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Benjamin Singer represents multinational corporations and their boards and executives in high-stakes criminal and civil investigations by the U.S. Department of Justice, Securities and Exchange Commission, and other federal and state agencies.  Ben joined O’Melveny after a decade at DOJ, where he most recently served as Chief of the Department of Justice’s Securities & Financial Fraud Unit.  In this role, Ben was the lead prosecutor on several of the largest cross-border cases in DOJ history, including Volkswagen’s alleged evasion of U.S. emissions standards, the foreign exchange manipulation cases, and cases alleging LIBOR manipulation.  Prior to that, Ben was the Chief of the DOJ’s Health Care Fraud Unit, where he supervised corporate health care prosecutions involving major health care providers, pharmaceutical manufacturers, and medical device manufacturers.

As Chief of the DOJ’s Securities & Financial Fraud Unit, Ben oversaw approximately 50 federal prosecutors investigating complex securities, commodities, and other corporate fraud and corruption offenses, including market manipulation, spoofing, insider trading, accounting fraud, procurement fraud, money laundering, environmental crimes, antitrust offenses, and bribery. 

As Chief of the DOJ’s Health Care Fraud Unit, Ben supervised a team of over thirty prosecutors that prosecuted offenses in the health care industry, including fraud, kickbacks, money-laundering, and FCPA-related offenses.


Government Experience

  • Chief, Securities & Financial Fraud Unit, Fraud Section, Criminal Division, U.S. Department of Justice (2014–2018)
  • Chief, Health Care Fraud Unit, Fraud Section, Criminal Division, U.S. Department of Justice (2013–2014)
  • Assistant Chief, Fraud Section, Criminal Division, U.S. Department of Justice (2011–2014)
  • Trial Attorney, Fraud Section, Criminal Division, U.S. Department of Justice (2009–2011)

Honors & Awards

  • Attorney General’s Award for Distinguished Service (2016)
  • Attorney General’s Award for Fraud Prevention (2012)
  • Department of Justice Director’s Award (2018)
  • Assistant Attorney General’s Award for Exceptional Service (2011, 2015)
  • Assistant Attorney General’s Award for Distinguished Service (2010, 2014)
  • Inspector General of the Department of Health and Human Services’ Integrity Award (2011)


Bar Admissions

  • New York*

Court Admissions

  • US District Court, Southern District of New York
  • US District Court, Eastern District of New York

*Admitted only in New York; supervised by principals of the firm.


  • Cornell Law School, J.D., 2002
  • The College of William & Mary, B.A., 1999: with honors

Professional Activities


  • “Second Circuit Decision Limits FCPA Jurisdiction as to Foreign Nationals Outside the United States,” O’Melveny & Myers LLP Client Alert (Aug. 28, 2018)
  • “Federal Appeals Court Refuses to Void Criminal Service of Process on Counsel for Foreign Corporation Making Limited Appearance,” O’Melveny & Myers LLP Client Alert (Aug. 23, 2018)
  • “California Decision Distorts Bank Liability Under FIRREA,” Law360 (July 17, 2018)

Speaking Engagements

  • UT Law 5th Annual Government Enforcement Institute, “Financial Fraud Enforcement Trends: A Conversation with the SEC and DOJ” (September 20-21, 2018)
  • Practicing Law Institute, Swaps and Derivatives and Market Enforcement, Panelist, “Perspectives from Government Agencies” (2016, 2017)
  • SEC & DOJ Hot Topics, Panelist, “Current Developments Materially Affecting Corporations, Financial Institutions, Individuals” (2016, 2017)
  • University of Texas School of Law, Annual Government Enforcement Institute, Keynote Speaker (2017); Panelist, “Current Trends in Criminal and Civil Investigations” (2015)
  • SIFMA, Compliance & Legal Annual Seminar, Panelist, “US and Global Market Abuses: Price Manipulation and Other Issues” (2016)
  • FDIC/DOJ Financial Crimes Conference, Keynote Speaker (2016) (included approximately 500 government-only participants)
  • Securities Litigation and Regulatory Practice Seminar, Panelist, “Enforcement Developments” (2016)
  • ABA Business Law Section, Derivatives & Futures Law Committee Winter Meeting, Panelist, “Enforcement/Litigation Developments” (2015)
  • American Bar Association, National Institute on Securities Fraud, Panelist, “Wall Street to the Hill: The Continuing Evolution of Insider Trading Investigations” (2014); Panelist, “Enforcement Priorities” (2015)
  • National Health Care Anti-Fraud Association, Annual Training Conference, Speaker “Medicare Fraud Strike Force and Beyond” (2011, 2012); Speaker, “Summary Evidence in Health Care Prosecutions” (2012)

In Government

  • Lead counsel for the United States in investigation of Volkswagen, Audi, and their current and former executives for fraud, violations of the Clean Air Act, and obstruction of justice in the “Dieselgate” emissions case, including negotiation of one of the largest fines in U.S. history.
  • Lead trial counsel for the United States in investigation and trial of CEO, CFO, and other key executives of a publicly-traded medical device manufacturer in a $750 million accounting fraud case.
  • Co-lead counsel for the United States in investigation of five global financial institutions for alleged manipulation in the foreign-exchange markets.
  • Trial counsel for the United States in trial of a senior executive of a health care company who participated in a $205 million billing fraud.
  • Lead trial counsel for the United States in trial of health care executive who participated in $70 million fraud on Medicare.
  • Supervised investigation of major financial institutions for alleged manipulation of LIBOR and related benchmark interest rates in the Southern and Eastern Districts of New York and negotiated related corporate resolutions.
  • Supervised investigation of Takata Corporation for alleged fraud in the sale of defective airbag inflators to its customers and helped negotiate related corporate resolution.
  • Supervised investigation and extradition of Navinder Sarao, the so-called “Flash Crash Trader” for fraud and spoofing in the commodities markets.
  • Supervised investigation of the largest bribery scandal in the history of the U.S. Navy, involving a Malaysian defense contractor known as “Fat Leonard” Francis, and his company, Glenn Defense Marine Asia.
  • Supervised investigation of two former employees of a global financial institution for defrauding one of its customers in a multi-billion dollar foreign exchange transaction through front-running and ramping.
  • Supervised investigation of a global pharmaceutical manufacturer for allegedly bribing physicians and government health officials in China in violation of the Foreign Corrupt Practices Act (FCPA).
  • Lead trial counsel for the United States in eight white-collar criminal trials involving securities fraud, wire fraud, mail fraud, health care fraud, money laundering, structuring, and identity theft.